ranitidine

(redirected from Zantac 75)
Also found in: Dictionary, Thesaurus.
Related to Zantac 75: Zantac 150

ranitidine

 [rah-nit´ĭ-dēn]
an antagonist of histamine H2receptors, used as the hydrochloride salt to inhibit stomach hydrochloric acid secretion in treatment of peptic ulcers, gastroesophageal reflux, and conditions of gastric hypersecretion, administered orally, intramuscularly, or intravenously.

ranitidine

(rə-nĭt′ĭ-dēn′)
n.
A histamine receptor antagonist, C13H22N4O3that inhibits gastric acid secretion and is used primarily to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease.

ranitidine

Zantac Therapeutics An H2-receptor antagonist used to treat peptic ulcer disease, gastric and duodenal ulcers, esophageal erosions, GERD, and conditions–eg, Zollinger-Ellison disease and systemic mastocytosis in which there is ↑ H2 activity due to blocking of the binding of histamine to H2 receptors, resulting in ↓ intracellular concentration of cAMP and acid secretion by gastric parietal cells Adverse reactions Diarrhea, headache, fatigue, myalgia, constipation, confusion, agranulocytosis, gynecomastia, impotence, allergic reactions, tachycardia, arrhythmias, interstitial nephritis, etc. See H2 blockers, Histamine receptor antagonists.

ranitidine

An H-2 (histamine-2) receptor antagonist drug used to reduce acid secretion in cases of peptic ulceration. A band name is Zantac. See also RANTITIDINE BISMUTH CITRATE.
References in periodicals archive ?
With the launch of Zantac 75, Warner-Lambert sought to improve its position as the fourth largest global marketer of OTC products.
In 1994, Warner-Lambert and Glaxo Wellcome began serious discussions regarding the coordinated OTC switch of Zantac 75. After an agreement was reached between the two companies, a joint venture steering committee was formed to manage broad issues, and a Zantac 75 OTC product team was established to handle the initial day-to-day activities and decisions surrounding the Zantac switch.
In late 1994, the Zantac 75 OTC team began the commercialization phase of the project.
Results were excellent, suggesting that Zantac 75 could be a substantial winner.
All trade classes believed that the product had great potential, and each was planning to aggressively support Zantac 75. To accomplish this, they wanted strong pharmacist support, consumer information, direct shipment delivery, complete marketing materials at the launch and advertising timed to coincide with the launch date (rather than a typical six- to eight-week advance campaign).
From the perspective of the salesforce, Zantac 75 presented an entirely new market category, an important entry process (OTC switch), a new brand and a broadly scoped launch lacking a specific launch date.
19, 1995, the FDA approved Zantac 75 for the OTC market.
Although the acid relief category is still in a state of flux, Warner-Lambert believes that products such as Zantac 75 are underrepresented.
"In the time Zantac 75 has been launched, while mass started out with an edge from the first week, after the first seven weeks, the food channel gained in share while mass slipped.
The plunge in the sales of Zantac 75 may be explained in part by consumers' preference for the higher-strength Zantac 150, for which sales increased by nearly 7 % over the past year, according to IRI.
Prilosec's addition repeated a pattern experienced several years ago when a number of products, including Pepcid, Zantac 75 and Glaxo's Tagamet, made the transition from Rx to O-T-C status.